Welcome to our dedicated page for Neogenomics SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeoGenomics, Inc. filings document the regulatory record of an oncology diagnostics company whose common stock trades on Nasdaq under the symbol NEO. Form 8-K reports furnish quarterly and annual operating results, preliminary financial information, press release exhibits, and Regulation FD disclosures tied to the company’s clinical testing and diagnostic services business.
The company’s proxy materials cover board structure, director matters, executive compensation, equity awards, pay-versus-performance disclosures and annual meeting governance. Other material-event filings describe officer transitions, board appointments and resignations, and registered security information, including common stock par value and exchange listing details.
NeoGenomics Inc. director John P. Kenny reported equity compensation and an option exercise involving company stock. He exercised restricted stock units into 5,893 shares of common stock at $0.00 per share and now holds 5,893 common shares directly.
He also received a grant of 15,970 restricted stock units and 11,069 stock options exercisable at $10.52 per share, both scheduled to vest or become exercisable on June 1, 2027. A separate stock option covering 4,171 shares at an exercise price of $11.76 remains outstanding and is scheduled to expire on January 1, 2036.
NeoGenomics, Inc. director Felicia Williams reported multiple equity compensation events. She exercised previously granted restricted stock units, receiving 23,077 shares of common stock at a price of $0.00 per share, and now directly owns 30,237 common shares following the transactions.
She was also granted 15,970 restricted stock units and 11,069 stock options with an exercise price of $10.52 per share, both relating to NeoGenomics common stock. In addition, she continues to hold options covering 16,107 shares at an exercise price of $7.28 per share expiring June 1, 2035, and 5,430 shares at $13.59 per share expiring June 1, 2034.
NeoGenomics director Lynn A. Tetrault reported equity award activity and updated holdings. On 2026-06-01, she acquired 23,077 shares of Common Stock through the exercise of previously reported restricted stock units at $0.00 per share, bringing her direct Common Stock holdings to 96,729 shares.
She also received new equity compensation in the form of 15,970 Restricted Stock Units and 11,069 Stock Options with an exercise price of $10.52 per share, both scheduled to vest or become exercisable on 2027-06-01. In addition, she holds 7,000 shares of Common Stock indirectly through the Lynn Tetrault Rollover IRA and maintains several previously granted option positions with exercise prices ranging from $7.28 to $41.76 and expirations through 2035.
NeoGenomics Inc. director David Brian Perez reported multiple equity compensation movements. On June 1, 2026, he exercised restricted stock units into 23,077 shares of common stock, bringing his direct common stock holdings to 56,967 shares. He also received a new grant of 15,970 restricted stock units, each convertible into one share of common stock, and a new stock option for 11,069 shares with a strike price of $10.52 per share expiring in 2036. Perez continues to hold 10,000 common shares indirectly through the Perez Joint Revocable Trust. The filing shows no open‑market buys or sells, only option and RSU grants and exercises related to compensation.
NeoGenomics director Michael Aaron Kelly reported equity compensation activity. On June 1, 2026, he exercised 23,077 restricted stock units into common stock at $0.00 per share, bringing his direct common stock holdings to 67,086 shares. A trust associated with him also holds 5,000 common shares indirectly.
He received a new grant of 15,970 restricted stock units and 11,069 stock options with a $10.52 exercise price, both scheduled to vest or become exercisable on June 1, 2027. The filing also lists several existing stock option awards with exercise prices ranging from $7.28 to $40.90 and expirations between 2027 and 2035, indicating a continuing long-term equity position.
NEOGENOMICS INC director Stephen M. Kanovsky reported equity compensation activity involving company stock. He exercised previously granted restricted stock units into 23,077 shares of Common Stock at $0.00 per share, bringing his direct Common Stock holdings to 75,421 shares. The filing notes this reflects the release of restricted stock units that were previously reported, and that once vested, the resulting shares are not subject to expiration.
Kanovsky also received new equity awards: 15,970 restricted stock units tied to Common Stock and a stock option for 11,069 shares of Common Stock with an exercise price of $10.52 per share, both scheduled to vest or become exercisable on June 1, 2027. He continues to hold multiple existing stock option grants with exercise prices ranging from $7.28 to $40.90 per share and expiration dates from 2026 through 2035, providing additional potential future share exposure.
NeoGenomics Inc. director Neil Gunn reported compensation-related equity activity. On 2026-06-01, 23,077 restricted stock units vested and were exercised into an equal number of common shares at $0.00 per share, bringing his direct common stock holdings to 51,177.31 shares.
Gunn also received new awards of 15,970 restricted stock units and 11,069 stock options with an exercise price of $10.52 per share, exercisable from 2027-06-01 and expiring on 2036-06-01. Existing stock options with exercise prices ranging from $7.28 to $14.82 and expirations from 2033-08-10 to 2035-06-01 remain outstanding.
NEOGENOMICS INC director Marjorie C. Green reported equity compensation activity and an option-related share issuance. She exercised previously reported restricted stock units into 22,964 shares of common stock, which she now holds directly. She also received new awards of 15,970 restricted stock units scheduled to vest on June 1, 2027 and 11,069 stock options exercisable at $10.52 per share expiring on June 1, 2036. A separate option position covering 16,019 underlying shares at an exercise price of $6.95 per share remains outstanding and expires on June 19, 2035. The filing shows only grants and exercises, with no open‑market purchases or sales.
NeoGenomics, Inc. reported results of its annual stockholder meeting. Stockholders approved a second amendment to the 2023 Equity Incentive Plan, increasing the shares authorized for issuance under the plan by 5,000,000 shares.
A total of 116,630,120 shares were present or represented by proxy, representing approximately 89.61% of outstanding voting stock as of March 23, 2026, ensuring a strong quorum. All nine director nominees were elected. Stockholders gave majority advisory approval to compensation for the Named Executive Officers, approved the incentive plan amendment, and ratified the appointment of Deloitte & Touche LLP as independent registered public accountant.
NEOGENOMICS, INC. reports amended beneficial ownership by Greenhouse Funds LLLP, Greenhouse GP LLC and Joseph Milano as joint filers. Each reporting person is shown with 9,215,903 shares of Common Stock, representing 7.1% of the class. The filing lists 8,318,358 shares with shared voting power and 9,215,903 shares with shared dispositive power.
The report states the shares are owned by advisory clients of Greenhouse Funds LLLP and includes a joint filing agreement and a control-person identification exhibit. Signatures by Joseph Milano dated 05/15/2026 appear on the amendment.